drugset / Trial / NCT04449939
A Study of Subcutaneous KY1005 in Healthy Volunteers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Single centre, open-label, single dose, parallel group study to investigate the PK, safety and tolerability of KY1005 after subcutaneous (s.c.) and intravenous (i.v.) administration, with i.v. KY1005 as a reference treatment.
Timeline
- Start
- 2020-07-07
- Primary completion
- 2020-11-30
- Completion
- 2020-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amlitelimab | Monoclonal antibody | — | Subcutaneous |